News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
24,636 Results
Type
Article (1009)
Company Profile (3)
Press Release (23624)
Section
Business (12558)
Career Advice (74)
Deals (1625)
Drug Delivery (2)
Drug Development (1960)
Employer Resources (2)
FDA (284)
Job Trends (500)
News (15612)
Policy (581)
Tag
Academia (17)
Accelerated approval (1)
Allergies (4)
Alliances (696)
ALS (4)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (5)
Approvals (295)
Artificial intelligence (4)
Autoimmune disease (6)
Automation (1)
Bankruptcy (5)
Best Places to Work (455)
Biosimilars (2)
Biotechnology (2)
Bladder cancer (5)
Breast cancer (18)
Cancer (127)
Cardiovascular disease (11)
Career advice (66)
Career pathing (1)
CAR-T (2)
Cell therapy (8)
Clinical research (1807)
Collaboration (10)
Compensation (34)
COVID-19 (29)
CRISPR (2)
C-suite (2)
Cystic fibrosis (6)
Data (190)
Depression (6)
Diabetes (13)
Diagnostics (218)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (2)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (3)
Earnings (12549)
Editorial (1)
Employer resources (2)
Events (1603)
Executive appointments (10)
FDA (466)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (13)
Gene editing (3)
Gene therapy (13)
GLP-1 (35)
Government (49)
Guidances (142)
Healthcare (586)
HIV (1)
IgA nephropathy (5)
Immunology and inflammation (7)
Indications (8)
Infectious disease (31)
Inflammatory bowel disease (4)
Influenza (1)
Intellectual property (2)
Interviews (15)
IPO (1272)
IRA (1)
Job creations (72)
Job search strategy (44)
Kidney cancer (4)
Labor market (2)
Layoffs (4)
Legal (107)
Liver cancer (1)
Lung cancer (26)
Lymphoma (18)
Manufacturing (11)
MASH (4)
Medical device (596)
Medtech (599)
Mergers & acquisitions (373)
Metabolic disorders (36)
mRNA (1)
Multiple sclerosis (2)
Neurodegenerative disease (7)
Neuropsychiatric disorders (5)
Neuroscience (86)
NextGen: Class of 2026 (127)
Non-profit (47)
Now hiring (1)
Obesity (19)
Opinion (5)
Pain (2)
Pancreatic cancer (5)
Parkinson's disease (12)
Patents (4)
Patient recruitment (9)
Peanut (1)
People (639)
Pharmacy benefit managers (1)
Phase 1 (420)
Phase 2 (716)
Phase 3 (726)
Pipeline (642)
Policy (2)
Postmarket research (94)
Preclinical (177)
Prostate cancer (6)
Radiopharmaceuticals (12)
Rare diseases (13)
Real estate (99)
Recruiting (1)
Regulatory (493)
Reports (1)
Research institute (34)
Resumes & cover letters (18)
Schizophrenia (5)
Series A (1)
Sickle cell disease (2)
Spinal muscular atrophy (5)
Sponsored (1)
Startups (53)
Supply chain (1)
Tariffs (2)
Vaccines (12)
Venture capital (3)
Weight loss (15)
Women's health (2)
Date
Today (33)
Last 7 days (66)
Last 30 days (142)
Last 365 days (1445)
2026 (173)
2025 (1443)
2024 (1542)
2023 (1779)
2022 (1971)
2021 (1931)
2020 (1663)
2019 (1198)
2018 (951)
2017 (713)
2016 (464)
2015 (569)
2014 (417)
2013 (210)
2012 (264)
2011 (361)
2010 (6765)
Location
Africa (11)
Alabama (3)
Arizona (8)
Arkansas (1)
Asia (1474)
Australia (203)
California (636)
Canada (136)
China (44)
Colorado (29)
Connecticut (25)
Delaware (14)
Europe (3147)
Florida (84)
Georgia (24)
Idaho (1)
Illinois (39)
India (1)
Indiana (38)
Japan (15)
Kansas (4)
Kentucky (2)
Louisiana (5)
Maine (7)
Maryland (61)
Massachusetts (321)
Michigan (8)
Minnesota (34)
Missouri (7)
Nevada (5)
New Hampshire (7)
New Jersey (152)
New York (135)
North Carolina (58)
Northern California (351)
Ohio (17)
Pennsylvania (129)
Puerto Rico (1)
South America (31)
South Carolina (1)
Southern California (240)
Tennessee (6)
Texas (59)
United States (1938)
Utah (17)
Virginia (6)
Washington State (36)
Wisconsin (4)
24,636 Results for "126".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
·
5 min read
Press Releases
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
February 17, 2026
·
12 min read
Press Releases
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
January 6, 2026
·
9 min read
Press Releases
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
·
5 min read
Press Releases
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
September 8, 2025
·
3 min read
Press Releases
Biologics Market Size to Lead USD 1,126.96 Billion by 2034 Driven by Rising Demand for Advanced Therapies and Technological Advancements
July 30, 2025
·
1 min read
Deals
Assembly Biosciences Announces $12.6 Million in Equity Financings
Assembly Biosciences, Inc. today announced that it has closed the issuance of shares of its common stock and warrants to Armistice Capital LLC (“Armistice Capital”), a healthcare-focused institutional investor, and Gilead Sciences, Inc. (“Gilead”), in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, before deducting expenses.
June 17, 2024
·
5 min read
Bio NC
Polarean Raises $12.6 Million in Oversubscribed Financing Round to Accelerate XENOVIEW™ Commercialization and Strategic Growth Initiatives
Polarean Imaging plc, a commercial-stage medical device leader in advanced Magnetic Resonance Imaging of the lungs, announces the closing of a $12.6 million oversubscribed financing via the Alternative Investment Market of the London Stock Exchange.
June 20, 2024
·
5 min read
BioCapital
Melanoma Research Alliance Announces $12.6 Million Investment in Cutting Edge Melanoma Research
The Melanoma Research Alliance, the world’s leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.
May 1, 2024
·
5 min read
1 of 2,464
Next
